Solid Tumor Mutation Panel by Next Generation Sequencing
2007991
Ordering Recommendation

Assess for targeted variants that are useful for prognosis and/or treatment of individuals with solid tumor cancers, including melanoma, gastrointestinal stromal tumor (GIST), colorectal, bladder, and hepatocellular carcinomas, at initial diagnosis or in the presence of refractory disease. If the clinical indication is lung cancer, additional molecular genetic testing may be considered for detection of gene rearrangements and/or c-MET exon 14-skipping alterations. For evaluation of microsatellite instability, additional molecular testing should be considered.

Mnemonic
SOLID NGS
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
12-14 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
 
Collect
Tumor tissue. 
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Diff-Quik and Papanicolaou stained cytology smears are also acceptable. Number of slides needed is dependent on the tumor cellularity of the smear. Slide(s) will be destroyed during testing process and will not be returned to client. Protect from excessive heat. Transport block and/or slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
Resections: Transport 8 unstained 5-micron slides. (Min: 5 slides)
Small Biopsies: Transport 15 unstained 5-micron slides. (Min: 10 slides) 
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. 
Unacceptable Conditions
Less than 10 percent tumor. Specimens fixed/processed in heavy metal fixatives. Decalcified specimens. FNA smears with less than 50 tumor cells. 
Remarks
Include surgical pathology report. 
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report.

Statement B: Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
A full list of the targeted genes and regions is listed in the Additional Technical Information.
Hotline History
View Hotline History
Components
Component Test Code*Component Chart NameLOINC
2007992Solid Tumor Panel by NGS Block ID
2007993Solid Tumor Panel By NGS Interpretation
2008147EER Solid Tumor Panel by NGS
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please view this test within the Laboratory Test Directory found at www.aruplab.com
Aliases
  • Solid Tumor Next Gen sequencing